Azienda Ospedaliera Regionale San Carlo
- Address
- Via Potito Petrone, 85100 Potenza, Italy
Azienda Ospedaliera Regionale San Carlo - Comprehensive Oncology & Critical Care Research Center
Azienda Ospedaliera Regionale San Carlo is a leading medical research institution specializing in advanced clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology research, with extensive investigations in both solid tumors and hematologic malignancies, as well as critical care medicine and cardiovascular disease prevention.
- Gastrointestinal and Colorectal Cancer: Advanced trials in metastatic colorectal cancer using targeted therapies (cetuximab, bevacizumab, panitumumab), biomarker-driven treatment strategies, liquid biopsy applications, and innovative neoadjuvant approaches for rectal cancer
- Lymphomas and Leukemias: Comprehensive studies in follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and Philadelphia chromosome-positive acute lymphoblastic leukemia, investigating novel immunotherapies including odronextamab and targeted agents
- Breast Cancer and Other Solid Tumors: Research in triple-negative breast cancer with immunotherapy, HER2-positive gastric cancer, and metastatic renal cell carcinoma
- Critical Care and Cardiovascular Medicine: Innovative trials in acute respiratory distress syndrome (ARDS), medical emergency interventions, cardiac surgery complications, and cardiovascular disease prevention
The center's research portfolio reflects a commitment to precision medicine and personalized treatment approaches, with particular emphasis on biomarker-driven therapies, liquid biopsy technologies, and combination treatment strategies. Notable research includes investigations of circulating tumor DNA (ctDNA) for treatment intensification, chemo-free strategies in hematologic malignancies, and novel drug combinations in both oncology and critical care settings. The center also participates in rare disease research, including studies in cystic fibrosis and specialized genetic mutations in cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 74 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Regionale San Carlo
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 74 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 6 | Unknown | 2013-01-11 | 2025-09-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.